Myriad Genetics (MYGN) Shares Outstanding (2009 - 2026)

Myriad Genetics (MYGN) has reported Shares Outstanding (Entity) for 18 consecutive years, with $94.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 2.39% year-over-year to $94.4 million; the TTM figure through Mar 2026 stood at $94.4 million (up 2.39% YoY), while the FY2025 annual figure was $93.5 million, up 2.41% from the prior year.
• Shares Outstanding (Entity) climbed to $94.4 million in Q1 2026 per MYGN's latest filing, from $93.5 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $94.4 million in Q1 2026 and bottomed at $80.3 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $87.6 million across 5 years, with a median of $90.5 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) increased 1.48% — and 2024, when it grew 11.04%.
• Myriad Genetics' Shares Outstanding (Entity) stood at $81.2 million in 2022, then rose by 10.71% to $89.9 million in 2023, then climbed by 1.56% to $91.3 million in 2024, then increased by 2.41% to $93.5 million in 2025, then increased by 0.96% to $94.4 million in 2026.
• Business Quant data shows MYGN's Shares Outstanding (Entity) at $94.4 million in Q1 2026, $93.5 million in Q4 2025, and $93.1 million in Q3 2025.